HK1146242A1 - 使用黑素皮質素治療胰島素敏感性 - Google Patents

使用黑素皮質素治療胰島素敏感性

Info

Publication number
HK1146242A1
HK1146242A1 HK11100510.8A HK11100510A HK1146242A1 HK 1146242 A1 HK1146242 A1 HK 1146242A1 HK 11100510 A HK11100510 A HK 11100510A HK 1146242 A1 HK1146242 A1 HK 1146242A1
Authority
HK
Hong Kong
Prior art keywords
melanocortins
insulin sensitivity
treat insulin
treat
sensitivity
Prior art date
Application number
HK11100510.8A
Other languages
English (en)
Inventor
Heather A Halem
Michael Dewitt Culler
Andrew A Butler
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1146242A1 publication Critical patent/HK1146242A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK11100510.8A 2007-11-05 2011-01-19 使用黑素皮質素治療胰島素敏感性 HK1146242A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US193307P 2007-11-05 2007-11-05
PCT/US2008/012490 WO2009061411A2 (en) 2007-11-05 2008-11-05 Use melanocortins to treat insulin sensitivity

Publications (1)

Publication Number Publication Date
HK1146242A1 true HK1146242A1 (zh) 2011-05-27

Family

ID=40626385

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11100510.8A HK1146242A1 (zh) 2007-11-05 2011-01-19 使用黑素皮質素治療胰島素敏感性
HK13112170.2A HK1184692A1 (zh) 2007-11-05 2013-10-29 黑皮質素治療胰島素敏感的應用
HK16109223.2A HK1221147A1 (zh) 2007-11-05 2016-08-02 使用黑素皮質素治療胰島素敏感性

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK13112170.2A HK1184692A1 (zh) 2007-11-05 2013-10-29 黑皮質素治療胰島素敏感的應用
HK16109223.2A HK1221147A1 (zh) 2007-11-05 2016-08-02 使用黑素皮質素治療胰島素敏感性

Country Status (21)

Country Link
US (6) US9155777B2 (zh)
EP (2) EP2979703B1 (zh)
JP (3) JP2011502987A (zh)
KR (3) KR101290623B1 (zh)
CN (2) CN103316345B (zh)
AR (1) AR069461A1 (zh)
AU (1) AU2008325194B2 (zh)
BR (1) BRPI0819188B1 (zh)
CA (2) CA2952095C (zh)
DK (1) DK2214693T3 (zh)
ES (2) ES2690556T3 (zh)
HK (3) HK1146242A1 (zh)
HU (1) HUE026842T2 (zh)
IL (2) IL205554A (zh)
NZ (1) NZ585131A (zh)
PL (1) PL2214693T3 (zh)
PT (2) PT2214693E (zh)
RU (1) RU2453328C2 (zh)
TR (1) TR201815292T4 (zh)
TW (1) TWI374030B (zh)
WO (1) WO2009061411A2 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618315T3 (es) * 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
ES2690556T3 (es) 2007-11-05 2018-11-21 Ipsen Pharma S.A.S. Uso de melanocortinas para tratar la sensibilidad a la insulina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
JP5805632B2 (ja) 2009-06-08 2015-11-04 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン受容体に特異的なペプチド
IN2012DN01493A (zh) * 2009-08-05 2015-06-05 Ipsen Pharma Sas
DK2473518T3 (en) * 2009-08-31 2017-03-27 Tensive Controls Inc Stabilized melanocortin ligands
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
BR112012011787B1 (pt) 2009-11-23 2022-03-03 Palatin Technologies, Inc Peptídeo cíclico e composição farmacêutica
UA114088C2 (xx) 2011-06-14 2017-04-25 Лікарська композиція з пролонгованим вивільненням для ін'єкцій
HRP20211950T1 (hr) * 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
WO2013138340A1 (en) 2012-03-13 2013-09-19 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
TR201815173T4 (tr) 2013-03-15 2018-11-21 Rhythm Pharmaceuticals Inc Peptit bileşimleri.
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
US10314883B2 (en) 2015-02-13 2019-06-11 University Of Virginia Patent Foundation Compositions and methods for regulating blood pressure
WO2017019952A1 (en) 2015-07-29 2017-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating leukocyte adhesion
WO2017049140A2 (en) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
US11124541B2 (en) * 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
CA3102603A1 (en) 2018-06-05 2019-12-12 The Research Foundation For The State University Of New York Method for passive wireless channel estimation in radio frequency network and apparatus for same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
JP2004510960A (ja) 2000-09-13 2004-04-08 エレノア　ルーズベルト　インスティテュート 肥満および糖尿病におけるインスリン抵抗性を治療する方法
WO2003099818A1 (en) * 2002-05-23 2003-12-04 Chiron Corporation Substituted quinazolinone compounds
EP1460070B1 (en) * 2003-03-20 2007-05-16 Santhera Pharmaceuticals (Schweiz) AG Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
WO2004087159A1 (en) 2003-03-26 2004-10-14 Merck & Co., Inc. Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
JP2007524584A (ja) 2003-05-09 2007-08-30 ノボ　ノルディスク　アクティーゼルスカブ 肥満の治療に使用するペプチド
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
EP1732586A1 (en) * 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
EP1807102A2 (en) * 2004-10-29 2007-07-18 Merck & Co., Inc. Compositions and methods for the treatment of obesity and sexual dysfunction
PT2236151E (pt) * 2005-07-08 2012-07-02 Ipsen Pharma Ligandos do receptor de melanocortina
EP1915168A4 (en) 2005-07-08 2010-03-31 Ipsen Pharma LIGANDS OF MELANOCORTIN RECEPTORS
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
ES2618315T3 (es) * 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
TW200848424A (en) * 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
ES2690556T3 (es) 2007-11-05 2018-11-21 Ipsen Pharma S.A.S. Uso de melanocortinas para tratar la sensibilidad a la insulina
IN2012DN01493A (zh) 2009-08-05 2015-06-05 Ipsen Pharma Sas

Also Published As

Publication number Publication date
PT2979703T (pt) 2018-10-31
US20160354429A1 (en) 2016-12-08
RU2010122897A (ru) 2011-12-20
US20150366934A1 (en) 2015-12-24
US9827286B2 (en) 2017-11-28
IL249998B (en) 2018-07-31
KR101662044B1 (ko) 2016-10-04
KR20100075680A (ko) 2010-07-02
RU2453328C2 (ru) 2012-06-20
EP2214693A2 (en) 2010-08-11
US9439943B2 (en) 2016-09-13
AU2008325194A1 (en) 2009-05-14
HUE026842T2 (en) 2016-08-29
US20180303899A1 (en) 2018-10-25
CN103316345A (zh) 2013-09-25
CN101980717A (zh) 2011-02-23
HK1184692A1 (zh) 2014-01-30
AR069461A1 (es) 2010-01-27
AU2008325194B2 (en) 2012-04-19
IL205554A (en) 2017-01-31
PT2214693E (pt) 2015-12-07
BRPI0819188B1 (pt) 2021-06-22
PL2214693T3 (pl) 2016-03-31
WO2009061411A2 (en) 2009-05-14
KR101290623B1 (ko) 2013-08-07
HK1221147A1 (zh) 2017-05-26
CA2952095A1 (en) 2009-05-14
US20220339239A1 (en) 2022-10-27
ES2555522T3 (es) 2016-01-04
DK2214693T3 (en) 2015-11-30
EP2979703B1 (en) 2018-07-18
US9155777B2 (en) 2015-10-13
TW200932258A (en) 2009-08-01
JP5964767B2 (ja) 2016-08-03
CA2704651A1 (en) 2009-05-14
JP2011502987A (ja) 2011-01-27
IL249998A0 (en) 2017-03-30
NZ585131A (en) 2012-10-26
TWI374030B (en) 2012-10-11
BRPI0819188A2 (pt) 2015-09-01
KR20150013339A (ko) 2015-02-04
JP2015131827A (ja) 2015-07-23
US20100311647A1 (en) 2010-12-09
TR201815292T4 (tr) 2018-11-21
KR20130065725A (ko) 2013-06-19
EP2214693B1 (en) 2015-09-09
CA2704651C (en) 2017-03-07
CN103316345B (zh) 2016-05-18
CA2952095C (en) 2020-02-18
JP2013144690A (ja) 2013-07-25
ES2690556T3 (es) 2018-11-21
WO2009061411A3 (en) 2010-04-15
EP2979703A1 (en) 2016-02-03
US20190111105A1 (en) 2019-04-18
EP2214693A4 (en) 2012-04-11
IL205554A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
HK1221147A1 (zh) 使用黑素皮質素治療胰島素敏感性
IL213596A0 (en) Heterocyclic compounds and methods of use
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (zh) 化合物和使用方法
HK1154054A1 (en) Predictors of patient response to treatment with egf receptor inhibitors
IL208354A0 (en) Methods of treatment
GB0707750D0 (en) Treatment of organic matter
HK1160925A1 (zh) 組織蛋白酶 的用途
PL2148676T3 (pl) Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
GB2448592B (en) Improvements to coffins
EP2470020A4 (en) BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
GB0723100D0 (en) Treatment of HFnEF
EP2066171A4 (en) ADMINISTERING A TREATMENT SUBSTANCE TO POROUS ELEMENTS
HK1156250A1 (zh) 阿帕地松單位劑量
GB0814296D0 (en) Improvements to coffins
GB0802903D0 (en) Treatment of diabetes
GB0801958D0 (en) Improvements relating to electro-optical sensors and their use
IL190834A0 (en) Improvements to bandages
GB0816217D0 (en) Treatment of hepatitis C
HU0800656D0 (en) Effective use of tea-composition
GB0809469D0 (en) Improvements relating to body jewelry
FI20080503A0 (fi) MSM-elementtien pintakäsittely
GB0717139D0 (en) Treatment of hepatitis C
GB0719334D0 (en) Improvements relating to electro-optical sensors and their use